The central goal of the Experimental Therapeutics Program is to promote the collaborative scientific interactions between basic scientists and clinicians involved in cancer research. The program seeks to bring together investigators with appropriate clinical, basic science, or technological expertise for the investigation of novel cellular, molecular, histopathologic and imaging endpoints in order to foster scientific research initiatives at the laboratory/clinic interface. The ultimate aim is to integrate the expertise of the bench researcher with the front-line clinician to foster clinical trial development.
Members of the Experimental Therapeutics Program conduct cancer research on a wide variety of topics/themes including:
- Functional Genomics
- Gene Expression Profiling
- Cancer Cell Signaling
- Tumor Microenvironments
- Metastatic Cascade
- Stem Cell Biology
- Non-invasive Imaging and Biomarkers
- Rodent and Large Animal Therapeutics
- Gene and Immunotherapy
- Vascular Directed Therapy
- Combined Modalities and Drug Resistance
- Dietary and Chemoprevention Strategies
- Early Phase Clinical Trials
Research conducted in the Experimental Therapeutics Program endeavors to advance innovative ideas from basic science and clinical practice in order to develop future front-line detection techniques and state of the art therapies for cancer patients.